Cognizant Is Cheap for a Reason — But Maybe Not a Bad Reason

# Cognizant Is Cheap for a Reason — But Maybe Not a Bad Reason

Let's get one thing out of the way: nothing in finance has a bullish probability of 1.0. Not Nvidia during the AI mania, not Berkshire in 1965, not a T-bill maturing tomorrow. So when a screener spits out "all four timeframes pointing up, probability 1.0" on Cognizant Technology Solutions, my first instinct is to check the math, not buy the ticker. My second instinct, after actually looking at the numbers, is that the underlying stock might still deserve a look — just not for the reasons the algorithm thinks.

What Actually Happened

Cognizant reported Q2 2026 on July 29. Revenue came in at $5.5 billion, up 4.5% year-over-year — fine, not exciting. Adjusted EPS of $1.37 missed consensus by a penny. A penny. That's not a thesis-breaker, but it's the kind of "technical miss" that headline writers love to dress up as more than it is, so let's not pretend it didn't happen.

The stuff that actually matters came elsewhere: management raised full-year adjusted EPS guidance to $5.70–$5.82, calling for 8–10% growth — a real upgrade, not a rounding error. They also plowed $1.15 billion into buybacks in a single quarter while simultaneously closing the $634 million Astreya acquisition. That's aggressive capital deployment on two fronts at once, and it tells you management isn't hoarding cash waiting for a recession — they think the stock and the business are both worth building on right now.

The Cheap Case Is Real

Strip away the noise and Cognizant trades at roughly 9x forward earnings with a free-cash-flow yield north of 13%. For an IT services company sitting on a fortress balance sheet — current ratio above 2, debt-to-equity around 0.14 — that's a multiple more associated with a business in terminal decline than one guiding EPS growth into double digits. Multiple independent valuation models land well above the current price: one puts fair value near $64, another near $72, and Wall Street's own consensus target sits at $66, with bulls stretching to $83–$91. Even discounting for analyst optimism, that's a lot of daylight between where the stock has traded and where the models say it should be.

The stock has already clawed back a chunk of a brutal drawdown, and there's evidence of institutional buyers stepping in around the $48–$52 zone as support. That's the kind of price action you'd expect if smart money agrees the valuation gap is a mispricing rather than a warning sign.

The Part Nobody Wants to Say Out Loud

Here's the tension: Cognizant is being pitched as an AI beneficiary, and the AI-services narrative on the earnings call was upbeat — accelerating adoption in financial services, new partnerships like Gulf Edge and a five-year insurance deal with Andover. Fine. But this is still a company growing revenue at 4.5%, carrying a "narrow moat" rating from the analysts who bother to assign one, and competing in a business — offshore IT services — that has spent two decades getting commoditized. AI cuts both ways here: it's either Cognizant's next growth leg, or it's the thing that eventually eats the legacy maintenance and BPO revenue that still pays a lot of the bills. Nobody knows yet which force wins, and anyone telling you they do with 100% confidence is selling something.

Add in the Astreya integration, which needs to actually work and not just look good on a slide, and the fact that the AI infrastructure buildout broadly has been flagged by financial-stability watchers as potentially over-extended — and "certain" starts to look like the wrong word entirely.

My Take

Cheap, well-capitalized, buying back stock hand over fist, and guiding higher — that's a legitimate setup, not a meme. But "all signals up, probability 1.0" is marketing dressed as analysis. Cognizant deserves a real look on valuation alone; it does not deserve blind faith. Buy the cheapness, not the certainty — and keep an eye on whether that AI story turns into actual bookings growth or just another slide in an investor deck. Q3 earnings, expected around November 4, will start to answer that question.